Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems.
| Title: | Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems. |
|---|---|
| Authors: | Goldstuck ND; a Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences , University of Stellenbosch, Belleville , Western Cape , South Africa. |
| Source: | Expert review of medical devices [Expert Rev Med Devices] 2017 Aug; Vol. 14 (8), pp. 593-599. Date of Electronic Publication: 2017 Jul 11. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101230445 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-2422 (Electronic) Linking ISSN: 17434440 NLM ISO Abbreviation: Expert Rev Med Devices Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Abingdon, Oxford : Taylor & Francis; Original Publication: London : Future Drugs Ltd. |
| MeSH Terms: | Intrauterine Devices, Medicated*; Contraceptive Agents, Female/*administration & dosage ; Levonorgestrel/*administration & dosage; Female ; Humans ; Terminology as Topic |
| Abstract: | Introduction: Jaydess/Skyla and Kyleena are 'low dose' levonorgestrel releasing intrauterine systems(LNG-IUS). They differ from Mirena and other similar LNG-IUSs in terms of pharmacological properties and physical dimensions. There are currently no defined guidelines to decide when to use Jaydess or Kyleena or Mirena. Areas covered: MEDLINE, POPLINE, PubMed and clinicaltrials.gov were searched using the terms 'Jaydess', 'Skyla', LNG-IUS 13.5mg and 'Kyleena' LNG-IUS 19.5mg. Only clinical research articles as opposed to generalised reviews and opinion papers on the newer LNG-IUSs were considered for review. There were 10 clinical research articles and 11 clinical research abstracts relating to Jaydess/Skyla(LNG-IUS13.5mg) and Kyleena(LNG-IUS 19.5mg). All the studies were sponsored by the manufacturer. There were no independent clinical research studies. Expert commentary: The clinical research information from studies on Jaydess/Skyla and Kyleena does not adequately inform the clinician when and where these IUSs should be used in preference to other LNG-containing IUSs. The terminology used for describing the new low dose LNG-IUSs is inconsistent. The clinical differences between Jaydess, Kyleena and Mirena and the clinical differences in parity of subjects using Jaydess or Kyleena is used to generate an algorithm for helping clinicians choose between Mirena and Jaydess/Skyla or Kyleena. |
| Contributed Indexing: | Keywords: Jaydess; Kyleena LNG-IUS 19.5mg; LARC; Skyla: LNG-IUS 13.5mg; intrauterine contraception: LNG-IUD |
| Substance Nomenclature: | 0 (Contraceptive Agents, Female); 5W7SIA7YZW (Levonorgestrel) |
| Entry Date(s): | Date Created: 20170705 Date Completed: 20180129 Latest Revision: 20181202 |
| Update Code: | 20260130 |
| DOI: | 10.1080/17434440.2017.1350169 |
| PMID: | 28675069 |
| Database: | MEDLINE |
Journal Article; Review